Cardiovascular diseases (CVDs) are the leading cause of death worldwide. One major disorder causing this situation is the so called atherosclerosis, blood vessel blocked by cholesterol. High levels of low-density lipoprotein cholesterol (LDL-C) are one of the major risk factors contributing to the formation of atherosclerotic plaques and are thereby strongly associate with CVD and related mortality.

To overcome the situation, a reliable and above all, a concerted cardiovascular risk assessment is absolutely essential.

DiaSys has recently extended its cardiovascular risk assessment portfolio by two innovative new reagents, HDL-c direct FS and LDL-c direct FS. Both are homogenous assays for direct determination. These reagents are manufactured in Germany and offer the high quality DiaSys is known for. With outstanding long calibration and onboard stabilities of up to 4 months; an economic usage for labs is ensured. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.